In order to ensure that the content to be conveyed are perceived equally by the target groups, irrespective of the individual medicinal product prescribed or used, that they do not lead to confusion on the part of the user and that the necessary training material is accepted as widely as possible (see also GVP Modul XVI Addendum I, EMA-Good Pharmacovigilance Practices), the training material should be uniform, even if the medicinal product is marketed by different pharmaceutical companies.
In addition, it may happen that training material is changed or supplemented by the original marketing authorisation holder at a later date. To ensure that only the current version is used, we refer to the training material of the original marketing authorisation holder in the current version.